ESMO Advanced Course on Cholangiocarcinoma: Where are we going?

ESMO ADVANCED COURSE

BARCELONA SPAIN
15-16 SEPTEMBER 2023

Co-Chairs
Stefano Cascinu, Italy
Angela Lamarca, Spain
ESMO ADVANCED COURSE PROGRAMME
CHOLANGIOCARCINOMA: WHERE ARE WE GOING?

Barcelona, Spain
15-16 September 2023

CO-CHAIRS
Sandro Cascini, Italy
Angela Lamarca, Spain

SPEAKERS
Chiara Braconi, United Kingdom
John Bridgewater, United Kingdom
Julien Edeline, France
Maeve Lowery, Ireland
Teresa Macarulla, Spain
Helen Morement, United Kingdom
Victor Moreno, Spain
Lorenza Rimassa, Italy
Arndt Vogel, Germany

LEARNING OBJECTIVES

- To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
- To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
- To discuss the role of locoregional therapy for cholangiocarcinoma
- To investigate the role of immunotherapy for the management of cholangiocarcinoma
- To explore currently available and novel targeted therapies and treatment options for advanced disease

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

SERVIER

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
## Friday, 15 September 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:10</td>
<td>Welcome and introduction</td>
</tr>
</tbody>
</table>
| 10’           | Welcome and learning objectives  
Stefano Cascinu, IT and Angela Lamarca, ES                                                           |
| 09:10-10:30   | **Session 1 – Knowing cholangiocarcinoma and the patients**  
What is cholangiocarcinoma (primary site, molecular biology, epidemiology)?  
Teresa Macarulla, ES  
Symptom management when treating patients with cholangiocarcinoma  
Stefano Cascinu, IT  
Patient perspective: What should the oncologist treating cholangiocarcinoma take into account?  
Helen Morement, UK  
Discussion                                                                |
| 10:30-11:00   | **Coffee break**                                                                                  |
| 11:00-12:00   | **Session 2 – Adjuvant and neoadjuvant treatment for cholangiocarcinoma**                           |
| 20’           | Adjuvant treatment: Is capecitabine the standard of care?  
John Bridgewater, UK                                                |
| 20’           | Neoadjuvant treatment: Is perioperative treatment coming or could it have a role?  
Lorenza Rimassa, IT                                                  |
| 20’           | Discussion                                                                                       |
| 12:00-12:40   | **Session 3 – Locoregional therapies for cholangiocarcinoma**                                     |
| 20’           | Locoregional therapies: How can we improve the study design  
Julien Edeline, FR                                                   |
| 20’           | Discussion                                                                                       |
| 12:40-13:40   | **Lunch**                                                                                       |
| 13:40-14:40   | **Session 4 – The management of advanced disease: Chemotherapy and immunotherapy**               |
| 20’           | Chemotherapy: First-line and second line. How is the field moving forward?  
Angela Lamarca, ES                                                   |
| 20’           | Immunotherapy: Rationale, current data, and upcoming studies  
Arndt Vogel, DE                                                       |
| 20’           | Discussion                                                                                       |
| 14:40-17:10   | **Session 5 – The management of advanced disease: Targeted therapies and new treatment options** |
| 20’           | Targeted therapies FGFR and IDH: Current data and compounds in advanced (phase II and beyond) stage of development  
Maeve Lowery, IE                                                      |
Targeted therapies beyond FGFR and IDH: Current data and compounds in advanced (phase II and beyond) stage of development
Chiara Braconi, UK

Discussion

Coffee break

What is coming – Phase I input – Novel IO strategies, cell therapy new compounds in phase I with potential activity
Victor Moreno, ES

Ongoing clinical trials – ongoing and soon-to-come phase II and phase III: To which trials shall I recruit my patients?
Teresa Macarulla, ES

Discussion

Networking dinner

Saturday, 16 September 2023

Workshop sessions
Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)
15’ Introduction based on clinical cases presented by speakers
40’ Discussion
5’ Break

Workshop 1 Adjuvant therapy
Julien Edeline, FR and Angela Lamarca, IT

Workshop 2 Palliative chemotherapy (+/- immunotherapy)
Stefano Cascinu, IT and Lorenza Rimassa, IT

Workshop 3 Targeted therapy
Chiara Braconi, UK and Maeve Lowery, IE

Coffee break

Workshops continuation

Feedback on the workshops from each group

Synthesis and wrap-up
Stefano Cascinu, IT and Angela Lamarca, ES

Lunch